PolyPeptide Group

We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.

Ad hoc announcements pursuant to Art. 53 LR

Results of Accelerated Bookbuild Offering of 1,500,000 Existing Shares in PolyPeptide Group AG

10 Nov 2021 - PolyPeptide Group AG (“PolyPeptide”) has been informed that Draupnir Holding B.V. (“Draupnir”), which held 60.0% of PolyPeptide’s share capital as of close of trading on SIX […]

Read more
Media releases

PolyPeptide customer Cara Therapeutics with FDA approval for novel treatment of moderate-to-severe pruritus in hemodialysis patients

1 Sep 2021 - Long-term collaborative development process for peptide API successfully completed and continued with commercial supply agreement PolyPeptide is pleased to announce that its customer Cara Therapeutics (Nasdaq: […]

Read more
Ad hoc announcements pursuant to Art. 53 LR

PolyPeptide reports strong H1 2021 revenue growth and operating leverage amidst favorable market environment and encouraging business trends

17 Aug 2021 - PolyPeptide Group AG (SIX: PPGN), a global leader in peptide custom development and manufacturing, today announced its results for the first half of 2021: – Revenue […]

Read more
Ad hoc announcements pursuant to Art. 53 LR

PolyPeptide Group appoints Christina Del Vecchio as General Counsel and member of the Executive Committee

25 Jun 2021 - PolyPeptide Group AG, a global leader in peptide development and manufacturing, today announced the appointment of Christina Del Vecchio as General Counsel and member of the […]

Read more
Business news

Proclamation honoring Jane Salik upon her retirement

11 May 2021 - The city of Torrance, California, honored Jane Salik for her investment in the Torrance community and her outstanding contributions to the Science and Peptide Industry. 05-11-21 […]

Read more
Ad hoc announcements pursuant to Art. 53 LR

PolyPeptide Group announces the exercise of the full over-allotment option

5 May 2021 - PolyPeptide Group AG ("PolyPeptide" or "the Group"), a global leader in peptide development and manufacturing, today announced that the Joint Global Coordinators have exercised in full the over-allotment option granted in connection with its Initial Public Offering (the "IPO") at the offer price of CHF 64 per share.

Read more
Business news

Stock exchange listing

29 Apr 2021 - Today the PolyPeptide Group became a public company. Our shares are being traded on SIX, the Swiss Stock Exchange.  What an exhilarating day! Today the PolyPeptide […]

Read more
Media releases

PolyPeptide Group appoints Raymond De Vré as new Chief Executive Officer

16 Feb 2021 - PolyPeptide Group, a global leader in peptide manufacturing and development, today announced the appointment of  as its new Chief Executive Officer. He will succeed Jane Salik […]

Read more
Business news

PolyPeptide News Flash, #1, 2021

28 Jan 2021 - Get to know Christelle Bobier, Director Global Engineering and Manufacturing Technology, in our newsletter. PolyPeptide Group maintained a strong and healthy pipeline that has gained a […]

Read more